KalVista Pharmaceuticals, Inc. / Fundamentals
Income statement
- Net revenue
€1.22M - Cost of goods sold
€314.03K - Gross profit
€909.48K - SG&A expenses
€123.01M - R&D expenses
€51.70M - EBITDA
-€161.60M - D&A
€615.19K - EBIT
-€173.99M - Interest expenses
€1.94M - EBT
-€169.50M - Tax expenses
€4.76M - Net income
-€174.26M
Cash flow statement
- Net deferred tax
€0.00 - Non-cash items
€6.87M - Changes in working capital
€21.10M - Operating cash flow
-€143.45M - Capex
-€18.02K - Other investing cash flow
-€53.45M - Net investing cash flow
€64.46M - Total cash dividends paid
€0.00 - Issuance of common stock
€50.86M - Debt repayment
€0.00 - Other financing cash flow
€104.03M - Net financing cash flow
€154.39M - Foreign exchange effects
€4.50M - Net change in cash
€79.89M - Cash at end of period
€107.22M - Free cash flow
-€143.47M
Balance sheet
- Cash and cash equivalents
€106.65M - Cash and short-term investments
€164.28M - Total receivables
€1.65M - Inventory
€0.00 - Other current assets
€10.73M - Total current assets
€176.66M - Property, plant & equipment
€6.21M - Goodwill
€0.00 - Intangible assets
€0.00 - Long-term investments
€0.00 - Other non-current assets
€2.04M - Total non-current assets
€8.24M - Total assets
€184.90M - Accounts payable
€5.04M - Short-term debt
€1.82M - Other current liabilities
€16.28M - Total current liabilities
€32.93M - Long-term debt
€3.45M - Deferred tax liabilities
€0.00 - Other non-current liabilities
€80.61M - Total non-current liabilities
€84.05M - Total liabilities
€116.98M - Common stock
€0.00 - Retained earnings
-€611.98M - Other equity
-€5.48M - Total equity
€35.00M - Total liabilities and shareholders' equity
€184.90M
Company information
- Market capitalization
€483.84M - Employees
150 - Enterprise Value
€507.67M
Company ratios
- Gross margin
-
74.3% Much better than peer group: -59,911,001,827,593.7% - EBITDA margin
-
-13,207.9% Much better than peer group: -330,257,133,200,420.4% - EBIT margin
-
-14,220.8% Much better than peer group: -333,325,756,459,374.2% - EBT margin
-
-13,853.3% Much better than peer group: -332,851,576,178,142.0% - Net margin
-
-14,242.4% Much better than peer group: -332,851,576,178,106.0% - ROE
-
-497.9% Much worse than peer group: 54.9% - ROA
-
-94.2% Much worse than peer group: -71.8% - Asset turnover
-
0.7% Worse than peer group: 16.0% - FCF margin
-
-11,722.9% Much better than peer group: -277,320,275,085,886.8% - FCF yield
-29.6% - Efficiency ratio
13,307.9% - Net sales per employee
-
€8.16K - Net income per employee
-
-€1.16M